Genemige Jun 2026

In 2000, Genmab entered into a collaboration with GlaxoSmithKline (GSK) to develop a therapeutic antibody for the treatment of rheumatoid arthritis. This partnership led to the development of the antibody, known as HuMax-CD20, which was later approved by the US FDA under the brand name Ofatumumab (Arzerra) for the treatment of chronic lymphocytic leukemia (CLL).

CRISPR-Cas9 remains the dominant tool for targeted DNA modification. It acts like "molecular scissors" to cut DNA at specific spots, allowing for the addition or removal of genetic material. genemige